Elanco has received USDA approval for TruCan™ Ultra B (Oral), the first ½ mL oral Bordetella bronchiseptica vaccine for dogs, designed to deliver proven protection with improved patient comfort.
Elanco Animal Health has received U.S. Department of Agriculture (USDA) approval for Befrena™ (tirnovetmab), an anti-IL31 monoclonal antibody injection providing long-lasting relief for dogs suffering from allergic and atopic dermatitis.
The FDA has granted full approval for Vetmedin (pimobendan) to delay the onset of congestive heart failure in dogs with preclinical myxomatous mitral valve disease—the first animal drug indication to transition from expanded conditional to full approval.
Elanco Animal Health has received full approval from the U.S. Department of Agriculture for Trutect™ (formerly CPMA), the first and only monoclonal antibody therapy proven to treat—and now prevent—deadly canine parvovirus.
Nutramax Laboratories Veterinary Sciences has launched Filaquin™, a new supplement formulated to support anal gland health in dogs through a proprietary fiber blend and postbiotic support.
The FDA has approved expanded labels for Elanco’s Credelio™ and Credelio Quattro™, adding prevention of Lyme disease and protection against the rapidly spreading longhorned tick—now found in 22 U.S. states.
Zoetis’ Lenivia® (izenivetmab) receives Health Canada approval and a positive opinion from the European Medicines Agency, paving the way for the world’s first three-month monoclonal antibody therapy for canine osteoarthritis pain.
The FDA has granted an Emergency Use Authorization for Elanco’s Credelio™ (lotilaner) to treat New World screwworm infestations in dogs—marking the first authorization of its kind as the parasite nears the U.S. border.
Phibro Animal Health has launched Restoris™, a new piezoelectric dental gel for dogs designed to promote bone growth and restore oral health in cases of periodontal disease.
Akston has initiated a Purdue University clinical trial of its Ambifect® immuno-enhancing protein therapy targeting PD-L1 in dogs with solid tumors — marking the company’s first in-clinic study of its novel Fc-fusion platform.